Medicine & Life Sciences
Chronic Obstructive Pulmonary Disease
100%
Type 2 Diabetes Mellitus
91%
Lung
65%
Asthma
49%
Lung Neoplasms
46%
Denmark
39%
Malignant Pleural Effusion
38%
Systematic Reviews
38%
Cohort Studies
36%
Randomized Controlled Trials
36%
Dyspnea
36%
Hydroxychloroquine
35%
Physiologic Monitoring
34%
Endoscopic Ultrasound-Guided Fine Needle Aspiration
32%
Respiration
32%
Pulmonologists
31%
empagliflozin
30%
Esophagus
29%
Inferior Vena Cava
28%
Biopsy
27%
Pleural Diseases
27%
Mortality
26%
Singing
26%
Bronchoscopy
26%
Fine Needle Biopsy
25%
Azithromycin
23%
Perfusion
23%
Confidence Intervals
21%
Placebos
21%
Neoplasms
20%
Thoracoscopy
20%
Telerehabilitation
20%
Breathing Exercises
19%
Adrenal Cortex Hormones
19%
Rehabilitation
19%
Glucagon-Like Peptide-1 Receptor
19%
Hermeneutics
18%
Therapeutics
17%
Health
17%
Non-Small Cell Lung Carcinoma
17%
Cardiovascular Diseases
17%
Magnetic Resonance Imaging
17%
Exercise
16%
Systemic Inflammatory Response Syndrome
16%
Pleural Effusion
16%
Meta-Analysis
15%
Coronavirus
15%
Diabetes Complications
15%
Delivery of Health Care
14%
Retrospective Studies
14%
Urinary Incontinence
14%
Venous Thromboembolism
14%
Left Ventricular Function
14%
Adrenal Glands
13%
Albuminuria
13%
Mental Competency
13%
Hospitalization
13%
Trachea
13%
Neoplasm Metastasis
13%
Gray Literature
13%
Liraglutide
12%
Nose
12%
Pneumothorax
11%
benralizumab
11%
Diabetic Cardiomyopathies
11%
Pneumonia
11%
Needles
11%
Endoscopes
11%
Hospital Emergency Service
11%
Quality of Life
11%
Tomography
11%
Sodium-Glucose Transport Proteins
11%
Pulmonary Blastoma
11%
indacaterol
11%
Economics
10%
Outpatients
10%
Epidemiology
10%
Fluoroscopy
10%
Databases
10%
Positron Emission Tomography Computed Tomography
10%
Incidence
10%
Prospective Studies
10%
Income
10%
Self-Management
10%
Sodium-Glucose Transporter 2 Inhibitors
9%
Epithelioid Hemangioendothelioma
9%
Glucagon-Like Peptide 1
9%
Bronchiectasis
9%
trimethyloxamine
9%
Pulmonary Medicine
9%
tetramethylrhodamine methyl ester
9%
fibroblast growth factor 23
9%
Obstructive Lung Diseases
9%
Omalizumab
9%
Silicones
9%
Inflammation
9%
Pragmatic Clinical Trials
9%
Point-of-Care Systems
9%
Pleural Empyema
9%
Immunoglobulin G4-Related Disease
9%